Mild Cognitive Impairment - Pipeline Review, H1 2019

Date: May 23, 2019
Pages: 131
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M54A2B801E4EN
Leaflet:

Download PDF Leaflet

Mild Cognitive Impairment - Pipeline Review, H1 2019
Mild Cognitive Impairment - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2019, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 9, 3, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Mild Cognitive Impairment - Overview
Mild Cognitive Impairment - Therapeutics Development
Mild Cognitive Impairment - Therapeutics Assessment
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
Mild Cognitive Impairment - Drug Profiles
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Mild Cognitive Impairment, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Mild Cognitive Impairment - Pipeline by AbbVie Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Biogen Inc, H1 2019
Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2019
Mild Cognitive Impairment - Pipeline by CuraSen Therapeutics Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H1 2019
Mild Cognitive Impairment - Pipeline by Fujifilm Toyama Chemical Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2019
Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2019
Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2019
Mild Cognitive Impairment - Pipeline by Protekt Therapeutics Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2019
Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2019
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2019
Mild Cognitive Impairment - Dormant Projects, H1 2019
Mild Cognitive Impairment - Dormant Projects, H1 2019 (Contd..1), H1 2019
Mild Cognitive Impairment - Discontinued Products, H1 2019

LIST OF FIGURES

Number of Products under Development for Mild Cognitive Impairment, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

AbbVie Inc
Addex Therapeutics Ltd
AgeneBio Inc
Avraham Pharmaceuticals Ltd
Biogen Inc
CereSpir Inc
CuraSen Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Fujifilm Toyama Chemical Co Ltd
Merck & Co Inc
Neuron Biopharma SA
Octapharma AG
Pfizer Inc
Protekt Therapeutics Ltd
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Therapix Biosciences Ltd
Skip to top


Mild Cognitive Impairment - Pipeline Review, H2 2018 US$ 2,000.00 Sep, 2018 · 106 pages

Ask Your Question

Mild Cognitive Impairment - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: